Skip to main content

Table 1 Summary of published cases in the English literature reported as of July 2012 of docetaxel-related interstitial pneumonitis

From: Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review

Reference Age Cancer Stage IV Pulmonary comorbidities Chemotherapy Docetaxel dose (mg/m2) Lung biopsy Steroid Outcome
[4] 44 to 77 NSCLC Y Y (67 percentage points) Docetaxel 60 N N/A N/A
[5] 69 Prostate Y N Docetaxel 75 N Y Death
[6] 46 Breast N N TAC 75 N Y Resolution
[6] 64 Breast Y N Docetaxel 75 N Y Death
[6] 52 Breast Y Y Docetaxel 100 N Y Resolution
[6] 48 Breast N N FEC then docetaxel 100 N Y Resolution
[7] 57 Gastric N Y Docetaxel/S-1 35 N Y Resolution
[8] 63 Breast N N DH 100 Y Y Death
[9] 71 GE junction N Y Docetaxel 75 N Y Resolution
[10] 65 Breast Y N Docetaxel/bevacizumab 100 Y Y Resolution
[11] 72 Prostate Y N Docetaxel 30 N Y Death
[12] U Breast U U Docetaxel U N Y Resolution
[13] 44 to 75 NSCLC Y Y Docetaxel/gemcitabine 30 to 40 N Y Two deaths/four resolutions
[14] 78 Prostate Y N Docetaxel/thalidomide 30 Y Y Resolution
[15] 73 Prostate Y N Docetaxel 75 Y Y Death
[15] 74 Breast Y Y Docetaxel 75 N N Death
[15] 61 Breast N N AC then docetaxel 75 Y Y Resolution
[15] 54 Breast Y Y Docetaxel 60 N Y Resolution
[16] 44 NSCLC Y Y Docetaxel 33 N Y Death
[16] 73 NSCLC Y Y Docetaxel/gemcitabine 30 Y Y Death
[16] 70 NSCLC Y Y Docetaxel/gemcitabine 30 Y Y Death
[16] 75 NSCLC Y Y Docetaxel 60 N Y Death
[18] 41 Breast Y Y ThCD 125 N Y Resolution
[18] 48 Breast Y Y ThCD 125 N Y Resolution
[17] 73 NSCLC Y N Docetaxel 100 Y Y Resolution
[17] 67 NSCLC Y N Docetaxel 100 Y Y Improvement
  1. AC doxorubicin, cyclophosphamide; DH docetaxel, trastuzumab; FEC 5-fluorouracil, epirubicin, cyclophosphamide; GE gastroesophageal; NSCLC non-small cell lung cancer; TAC docetaxel, doxorubicin, cyclophosphamide; ThCD thiotepa, cyclophosphamide, docetaxel; U unknown.